The result is a paradox. Even before the HTA Review is formally concluded, announced, and implemented, the environment it was meant to reform has already worsened. Expectations that the review would stabilise or improve conditions now need to be recalibrated. The baseline has moved, and not in a favourable direction. …
To what extent does the system even see itself as bound by external review?
March 25, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
Liberty expands into Asia Pacific life sciences insurance with new tailored offering
March 25, 2026 - - Australian Biotech -
Budget delivers progress, but hundreds of thousands still waiting for access
March 25, 2026 - - Latest News -
To what extent does the system even see itself as bound by external review?
March 25, 2026 - - Latest News -
PBAC agenda reflects increasing number of companies seeking revised recommendations
March 25, 2026 - - Latest News -
Community pharmacies set to expand patient care following Labor re-election in South Australia
March 25, 2026 - - Latest News -
Clarity advances US manufacturing strategy with major copper 64 supply agreement
March 25, 2026 - -
As 'Horizon Europe' winds down, its successor program remains a work in progress
March 25, 2026 - - Latest News